Phase 1 Study of LQT-1213 in Healthy Adults

Summary

This is a single-center, randomized, double-blind, placebo-controlled study to be conducted in 2 parts: single ascending dose (SAD) incorporating a food effect arm and multiple ascending dose (MAD). Potential participants for each part will undergo screening procedures within 28 days of enrollment.

Timeline

Start

2022-09-14

Primary completion

2023-03-05

Completion

2023-03-05

Drugs

Indications